Life and Therapeutics After Multiple Concussions

Rico Petrini is a former 4 year starter at Linebacker with Oregon State University and Hall of Fame 4-sport athlete at Serra High School in San Mateo, CA. During his time playing football, Rico sustained over 15k subconcussive hits and 25+ concussions.

Rico felt that he had survived his time playing with no major lasting impact to himself, until March of 2021 when he experienced ‘systemic’ failure of his brain and body affecting mood, behavior, sleep, cognitive, and physical functions. Within a six month period, Rico’s decline was aggressive and severe, with referrals to multiple medical specialists and hospitals to try and determine the root cause which with every symptom tracked back to neuro in nature.

In July of 2021, Rico was enrolled in a Open Study at the University of Utah on the use of red light for football players with traumatic brain injury and/or suspected CTE. Through the use of red light over the past five years and other supplements or protocols, Rico is now functionally operating at or near his pre-symptom state.

Rico now uses his brokenness to be of service to others in the TBI and CTE community offering support and guidance for persons with brain injury and their caregivers based on his shared experience. You can find Rico at facebook.com/groups/cteandtbiwarriorcircle

Dr. Michael Wyand and Dr. Vishal Bansal Team up for Major Change in Concussion Crisis

Dr. Michael Wyand, DVM, PhD is a biopharmaceutical executive with over twenty-five years experience in managing and building successful product and service oriented life science companies. He is the CEO and Director of Oxeia Biopharmaceuticals, a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction.

Dr. Vishal Bansal, M.D. F.A.C.S. is the Chief Scientific Officer and Co-Founder of Oxeia Biopharmaceuticals. Since 2015, Dr. Bansal is a Director of Trauma Surgery at Scripps Mercy Hospital in San Diego.

Oxeia Biopharmaceuticals is a privately held clinical stage biotech company developing drug treatments for concussion and underlying neuro-metabolic dysfunction. Oxeia has completed phase 2a testing on OXE103, a synthetic human ghrelin, an endogenous hormone. OXE103 freely crosses the blood-brain barrier addressing underlying neuro-metabolic dysfunction and axonal injury. OXE103 uniquely targets the hippocampus region of the brain, an area important for cognition and memory.

Oxeia’s phase 2a study showed robust treatment effect across study endpoints with 85% of OXE103 patients improving while only 33% improved with standard care alone. This was the first time any drug showed meaningful improvement in persistent concussion symptoms. Meaningful improvements were made in the reduction of symptom severity and the quality of life. See: oxeiabiopharma.com and startengine.com/offering/oxeia-biopharma for investment opportunity.